- Home
- CMP vs OCS Comparison
CMP vs OCS Comparison
Compare CMP & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMP
- OCS
- Stock Information
- Founded
- CMP 1993
- OCS 2003
- Country
- CMP United States
- OCS Switzerland
- Employees
- CMP N/A
- OCS N/A
- Industry
- CMP Other Metals and Minerals
- OCS Biotechnology: Pharmaceutical Preparations
- Sector
- CMP Basic Materials
- OCS Health Care
- Exchange
- CMP Nasdaq
- OCS Nasdaq
- Market Cap
- CMP 781.2M
- OCS 869.8M
- IPO Year
- CMP 2003
- OCS N/A
- Fundamental
- Price
- CMP $19.10
- OCS $19.90
- Analyst Decision
- CMP Hold
- OCS Strong Buy
- Analyst Count
- CMP 3
- OCS 4
- Target Price
- CMP $20.00
- OCS $41.00
- AVG Volume (30 Days)
- CMP 407.0K
- OCS 35.1K
- Earning Date
- CMP 08-11-2025
- OCS 11-06-2025
- Dividend Yield
- CMP N/A
- OCS N/A
- EPS Growth
- CMP N/A
- OCS N/A
- EPS
- CMP N/A
- OCS N/A
- Revenue
- CMP $1,225,200,000.00
- OCS $960,668.00
- Revenue This Year
- CMP $12.05
- OCS $36.75
- Revenue Next Year
- CMP $4.15
- OCS $1,261.53
- P/E Ratio
- CMP N/A
- OCS N/A
- Revenue Growth
- CMP 7.27
- OCS N/A
- 52 Week Low
- CMP $8.60
- OCS $14.00
- 52 Week High
- CMP $22.69
- OCS $23.08
- Technical
- Relative Strength Index (RSI)
- CMP 52.47
- OCS 71.29
- Support Level
- CMP $18.27
- OCS $17.26
- Resistance Level
- CMP $20.39
- OCS $17.80
- Average True Range (ATR)
- CMP 0.76
- OCS 0.49
- MACD
- CMP 0.08
- OCS 0.23
- Stochastic Oscillator
- CMP 56.59
- OCS 96.01
About CMP Compass Minerals Intl Inc
Compass Minerals currently produces two primary products: salt and specialty potash fertilizer. The company's main assets include rock salt mines in Ontario, Louisiana, and the United Kingdom. The fertilizer is produced from a brine operation at the Great Salt Lake in Utah that produces sulfate of potash and magnesium chloride. Compass' salt products are used for deicing and also by industrial and consumer end markets. The firm's sulfate of potash is used by growers of high-value crops that are sensitive to standard potash.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.